S SERVIER
Updates & Highlights
ArchDaily México · 12 days ago
Gallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
MSN · 12 days ago
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
MSN · 13 days ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at SERVIER?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentGallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
Gallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
ArchDaily México · 12 days ago
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
MSN · 12 days ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
MSN · 13 days ago
Biopharma bites: Beren readies for Niemann-Pick launch, layoffs at Teva, and more from Servier, Sensorion and Lilly
Biopharma bites: Beren readies for Niemann-Pick launch, layoffs at Teva, and more from Servier, Sensorion and Lilly
FirstWord Pharma · 13 days ago
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
Endpoints News · 13 days ago
Servier partners with n-Lorem to advance rare neurology research
Servier partners with n-Lorem to advance rare neurology research
The Pharma Letter · 13 days ago
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
PR Newswire · 14 days ago
Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast
Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast
biocentury.com · 15 days ago
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Medical Dialogues · 20 days ago
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
Oncodaily · 21 days ago
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
TradingView · 21 days ago
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
BioXconomy · 21 days ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Pharmaceutical Technology · 22 days ago
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
MedCity News · 22 days ago
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
FirstWord Pharma · 22 days ago
Edgewise sells muscular dystrophy assets to Servier for $2.65B
Edgewise sells muscular dystrophy assets to Servier for $2.65B
BioWorld News · 22 days ago
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
BioSpace · 22 days ago
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
pharmaphorum · 22 days ago
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharmaceutical Executive · 22 days ago
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
European Biotechnology Magazine · 22 days ago